Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

por Charles, Edgar D., Neuschwander‐Tetri, Brent A., Pablo Frias, Juan, Kundu, Sudeep, Luo, Yi, Tirucherai, Giridhar S., Christian, Rose
Publicado 2018

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled...

por Catlett, Ian M., Nowak, Miroslawa, Kundu, Sudeep, Zheng, Naiyu, Liu, Ang, He, Bing, Girgis, Ihab G., Grasela, Dennis M.
Publicado 2020